TREMFYA ® is the first and only approved, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23. IL-23 is a cytokine secreted by ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the first drug in the class available in both intravenous and subcutaneous ...

Johnson & Johnson (J&J) has shared positive long-term results from a phase 3 trial of its dual-acting IL-23 inhibitor Tremfya ...

The company noted that TREMFYA is positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks.

The European Commission (EC) has approved a Marketing Authorization (MA) for Tremfya (guselkumab) to treat adults with ...

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...